Stefan Peukert

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

23h-index2.5kcitations59works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac electrophysiology and arrhythmias(11), Ion channel regulation and function(11), Hedgehog Signaling Pathway Studies(11), Asymmetric Synthesis and Catalysis(6), Epigenetics and DNA Methylation(6)

Publications59 total

Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
eLife·2025· 1 citedOpen Access
Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
2025Open Access
Author response: Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
2025Open Access
Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
2025Open Access
Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
eLife·2025Open Access
Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules
2025Open Access
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes
Journal of Medicinal Chemistry·2023· 3 citedOpen Access
Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation
Bioorganic & Medicinal Chemistry Letters·2023· 5 citedOpen Access
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders
Journal of Medicinal Chemistry·2020· 32 citedOpen Access
Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
2019
Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Cancer Research·2019· 1 cited
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
Journal of Medicinal Chemistry·2018· 123 citedOpen Access
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer
Journal of Medicinal Chemistry·2017· 41 citedOpen Access
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
European Journal of Medicinal Chemistry·2015· 52 citedOpen Access
Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists
ACS Medicinal Chemistry Letters·2014· 51 citedOpen Access
Cover Picture: Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened (ChemMedChem 8/2013)
ChemMedChem·2013· 2 cited
Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened
ChemMedChem·2013· 88 cited
Analogue‐Based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin.
ChemMedChem·2011
A method for estimating the risk of drug-induced phototoxicity and its application to smoothened inhibitors
MedChemComm·2011· 23 cited
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Science Translational Medicine·2010· 553 cited
page 1 of 3Next →

Frequent Co-authors

Joseph F. Kelleher(9), Yingchuan Sun(9), Karen Miller‐Moslin(8), Joachim Brendel(8), Juliet Williams(7), Anthony Vattay(7), Jing Yuan(7), Marion Dorsch(7), Ribo Guo(6), Jill Nunez(6), Bernard Pirard(6), Silvia Buonamici(5), Rui Zhang(5), Samantha J Cassell(5), Simon Krautwald(5), Maryam Khoshouei(5), Yan Tony Lee(5), Jia Hou(5), Wendy Guan(5), Wilhelm A. Weihofen(5)